InspireMD
bg-home-hero

A new layer
of defense

CGuard® Prime is the next generation of carotid stenting, featuring a unique dual-layer design with a finely woven MicroNet™ mesh covering—taking stroke prevention to a new level
Explore CGuard Prime
home-hero-surgeon-e
Your new layer of defense against the significant risk of plaque prolapse and embolization
arterybody
embolism
Stroke is the third leading cause of death globally1
Approximately 2/3 of major adverse events occurred after CAS procedures, likely caused by late emboli through the struts of the stent2
~67%
home-cguard-stats
CGuard Prime demonstrated low rates of major adverse events
0.95%
through 30 days
Death, any Stroke, or MI† (DSMI)
The lowest independently adjudicated 30-day and 1-year primary endpoint major adverse event rates of any pivotal study of carotid intervention3-12
More Evidence
1.93%
through 1 year
DSMI through 30 days plus ipsilateral stroke through 1 year 3‡
Smart design for stroke prevention

Defense designed
by InspireMD

We're advancing carotid intervention with innovative designs that are reshaping industry standards for stroke prevention and neuroprotection.
Why InspireMD?
For Investors
Latest News
Press Releases

Dual-layered, dual benefits

SmartFit™
Flexibility
Conformable design allows for adaptability to wide ranging anatomies while eliminating the need for a tapered configurations
More Flex
MicroNet™
Protection
Non-metallic mesh with the smallest closed cells wraps around the stent for enhanced plaque prolapse prevention
More Mesh

Expert experiences

Hear from leading physicians about the clinical and patient benefits of CGuard
testimonial-alberto-cremonesi

Dr. Alberto Cremonesi

Chief of the Cardiovascular Department at Maria Cecilia Hospital
Cotignola, Italy
testimonial-antonio-moreno

Dr. Antonio Moreno

Chief Medical Officer of Endovascular Intervention World MEDICA
Madrid, Spain
testimonial-roberto-chiappa

Dr. Roberto Chiappa

Vascular Surgeon, Sandro Pertini Hospital
Rome, Italy
All Testimonials

What's New

Press Releases
Events

The CGuard Prime , when used in conjunction with embolic protection devices specified in the labeling, is indicated for improving carotid luminal diameter in patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization and meet both criteria outlined below:

  • Patients with neurological symptoms and ≥ 50% stenosis of the common or internal carotid artery by angiogram, or patients without neurological symptoms and ≥ 80% stenosis of the common or internal carotid artery by angiogram.
  • Patients having a vessel with reference diameters between 6.4mm and 9.0mm at the target lesion.

The CGuard Prime should be used in conjunction with the Abbott Emboshield NAV6™ Embolic Protection System or the Medtronic Mo.Ma™ Ultra Proximal Cerebral Protection Device.

CGuard® and the InspireMD Logo are registered trademarks of InspireMD, Inc.

Abbott® and Emboshield NAV6™ are registered trademarks of Abbott Laboratories.

Medtronic® and Mo.Ma™ are registered trademarks of Medtronic Corporation.

† myocardial infarction

‡ Based on modified intent-to-treat Kaplan-Meier analysis

References:
  1. World Health Organization Fact Sheet. Top 10 causes of death. 2024
  2. M. Bosiers, G. de Donato et al. Does Free Cell Area Influence the Outcome in Carotid Artery Stenting? European Journal of Vascular and Endovascular Surgery. Volume 33, Issue 2, 2007. https://doi.org/10.1016/j.ejvs.2006.09.019.
  3. InspireMD, Inc. C-GUARDIANS Pivotal Trial: Primary Endpoint Clinical Study Report. Version F (Protocol PRO-9017).
  4. Yadav JS, et al. N Engl J Med. 2004 Oct;351(15):1493-1501. doi: 10.1056/ NEJMoa040127.
  5. Matsumura JS, et al. J Vasc Surg. 2012 Apr;55(4):968-76. doi: 10.1016/j.jvs.2011.10.120.
  6. Higashida R, et al. Stroke vol. 41,2 (2010): e102-9. doi: 10.1161/STROKEAHA.109.564161.
  7. Brott TG, et al. N Engl J Med. 2010 Jul;363(1):11-23. doi: 10.1056/NEJMoa0912321. Epub 2010 May 26.
  8. Kwolek CJ, et al. J Vasc Surg. 2015 Nov;62(5):1227-34. doi: 10.1016/j.jvs.2015.04.460.
  9. U.S. Food and Drug Administration. Summary of safety and effectiveness data (SSED): Roadsaver/CASPER Carotid Stent System (PMA P210030). Published November 20, 2024
  10. Gray WA, et al. J Am Coll Cardiol Intv. 2025 Feb;18(3):367-76. doi: 10.1016/j.jcin.2024.10.031.
  11. Safian RD, et al. J Am Coll Cardiol. 2006 Jun;47(12):2384-89. doi: 10.1016/j.jacc.2005.12.076.
  12. Langhoff R, et al. Cardiovasc Intervent Radiol. 2025 Mar;Vol 48 427–37. doi: 10.1007/s00270-025-04003-z.
Contact Us
Contact Us
Stay Connected